Aronora Announces Clinical Data to Be Presented at the 64th American Society of Hematology Annual Meeting
PORTLAND, Ore., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Aronora Inc., a clinical-stage biotechnology company developing next-generation therapeutics for blood clotting diseases, announced today that clinical data from a phase 2 study of Gruticibart will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, taking place in New Orleans, Dec. 10-13, 2022.